Drug Profile
Research programme: hepatitis C virus therapy - Rigel
Latest Information Update: 20 Mar 2009
Price :
$50
*
At a glance
- Originator Rigel Pharmaceuticals
- Class
- Mechanism of Action Hepatitis C virus replication inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 11 Nov 2005 This programme is still in active development
- 22 Dec 2003 Preclinical trials in Hepatitis C treatment in USA (unspecified route)